| Drug Name: | Sumatriptan (103628-46-2) |
|---|---|
| PubChem ID: | 5358 |
| SMILES: | CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C |
| InchiKey: | KQKPFRSPSRPDEB-UHFFFAOYSA-N |
| Therapeutic Category: | Cardiovascular Agents, Neurotransmitter Agents, Serotonin 5-HT1 Receptor Agonists, Serotonin Agents, Serotonin Receptor Agonists, Vasoconstrictor Agents |
| Molecular Weight (dalton) | : | 295.408 |
| LogP | : | 1.3212 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 3 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 65.2 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| dihydroergotamine (6190-39-2) | Coronary Vasoconstriction | Additives | the drugs may have additive vasoconstrictive effects | The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Inhibited Calcitonin Gene-Related Peptide (Cgrp) | Calcitonin gene-related peptide (P06881) | Sumatriptan inhibited Calcitonin gene-related peptide (CGRP) release via the 5-HT1-receptor. [ ADR Type 1 ] | Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide |
| Inhibition Of Calcitonin Gene-Related Peptide (Cgrp) | 5-HT1-receptor (Q32Z81) | Sumatriptan inhibited Calcitonin gene-related peptide (CGRP) release via the 5-HT1-receptor. [ ADR Type 1 ] | Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category